BACKGROUND:Major depressive disorder (MDD) is a highly heterogeneous condition in terms of symptom presentation and, likely, underlying pathophysiology. Accordingly, it is possible that only certain individuals with MDD are well-suited to antidepressants. A potentially fruitful approach to parsing this heterogeneity is to focus on promising endophenotypes of depression, such as neuroticism, anhedonia, and cognitive control deficits. METHODS: Within an 8-week multisite trial of sertraline v. placebo for depressed adults (n = 216), we examined whether the combination of machine learning with a Personalized Advantage Index (PAI) can generate individualized treatment recommendations on the basis of endophenotype profiles coupled with clinical and demographic characteristics. RESULTS: Five pre-treatment variables moderated treatment response. Higher depression severity and neuroticism, older age, less impairment in cognitive control, and being employed were each associated with better outcomes to sertraline than placebo. Across 1000 iterations of a 10-fold cross-validation, the PAI model predicted that 31% of the sample would exhibit a clinically meaningful advantage [post-treatment Hamilton Rating Scale for Depression (HRSD) difference ⩾3] with sertraline relative to placebo. Although there were no overall outcome differences between treatment groups (d = 0.15), those identified as optimally suited to sertraline at pre-treatment had better week 8 HRSD scores if randomized to sertraline (10.7) than placebo (14.7) (d = 0.58). CONCLUSIONS: A subset of MDD patients optimally suited to sertraline can be identified on the basis of pre-treatment characteristics. This model must be tested prospectively before it can be used to inform treatment selection. However, findings demonstrate the potential to improve individual outcomes through algorithm-guided treatment recommendations.
RCT Entities:
BACKGROUND: Major depressive disorder (MDD) is a highly heterogeneous condition in terms of symptom presentation and, likely, underlying pathophysiology. Accordingly, it is possible that only certain individuals with MDD are well-suited to antidepressants. A potentially fruitful approach to parsing this heterogeneity is to focus on promising endophenotypes of depression, such as neuroticism, anhedonia, and cognitive control deficits. METHODS: Within an 8-week multisite trial of sertraline v. placebo for depressed adults (n = 216), we examined whether the combination of machine learning with a Personalized Advantage Index (PAI) can generate individualized treatment recommendations on the basis of endophenotype profiles coupled with clinical and demographic characteristics. RESULTS: Five pre-treatment variables moderated treatment response. Higher depression severity and neuroticism, older age, less impairment in cognitive control, and being employed were each associated with better outcomes to sertraline than placebo. Across 1000 iterations of a 10-fold cross-validation, the PAI model predicted that 31% of the sample would exhibit a clinically meaningful advantage [post-treatment Hamilton Rating Scale for Depression (HRSD) difference ⩾3] with sertraline relative to placebo. Although there were no overall outcome differences between treatment groups (d = 0.15), those identified as optimally suited to sertraline at pre-treatment had better week 8 HRSD scores if randomized to sertraline (10.7) than placebo (14.7) (d = 0.58). CONCLUSIONS: A subset of MDDpatients optimally suited to sertraline can be identified on the basis of pre-treatment characteristics. This model must be tested prospectively before it can be used to inform treatment selection. However, findings demonstrate the potential to improve individual outcomes through algorithm-guided treatment recommendations.
Authors: Maurizio Fava; A John Rush; Jonathan E Alpert; G K Balasubramani; Stephen R Wisniewski; Cheryl N Carmin; Melanie M Biggs; Sidney Zisook; Andrew Leuchter; Robert Howland; Diane Warden; Madhukar H Trivedi Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Diego A Pizzagalli; Elena Goetz; Michael Ostacher; Dan V Iosifescu; Roy H Perlis Journal: Biol Psychiatry Date: 2008-02-01 Impact factor: 13.382
Authors: Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Robert Gallop; Richard C Shelton; Jay D Amsterdam Journal: Behav Res Ther Date: 2013-04-12
Authors: Atul R Mahableshwarkar; John Zajecka; William Jacobson; Yinzhong Chen; Richard S E Keefe Journal: Neuropsychopharmacology Date: 2015-02-17 Impact factor: 7.853
Authors: Marta M Maslej; Toshiaki A Furukawa; Andrea Cipriani; Paul W Andrews; Benoit H Mulsant Journal: JAMA Psychiatry Date: 2020-06-01 Impact factor: 21.596
Authors: Rajapillai L I Pillai; Chuan Huang; Andrew LaBella; Mengru Zhang; Jie Yang; Madhukar Trivedi; Myrna Weissman; Patrick McGrath; Maurizio Fava; Benji Kurian; Crystal Cooper; Melvin McInnis; Maria A Oquendo; Diego A Pizzagalli; Ramin V Parsey; Christine DeLorenzo Journal: J Affect Disord Date: 2019-05-28 Impact factor: 4.839
Authors: Christian A Webb; Zachary D Cohen; Courtney Beard; Marie Forgeard; Andrew D Peckham; Thröstur Björgvinsson Journal: J Consult Clin Psychol Date: 2020-01
Authors: Yuen-Siang Ang; Roselinde Kaiser; Thilo Deckersbach; Jorge Almeida; Mary L Phillips; Henry W Chase; Christian A Webb; Ramin Parsey; Maurizio Fava; Patrick McGrath; Myrna Weissman; Phil Adams; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Thomas Carmody; Gerard Bruder; Crystal M Cooper; Cherise R Chin Fatt; Madhukar H Trivedi; Diego A Pizzagalli Journal: Biol Psychiatry Date: 2020-04-23 Impact factor: 13.382
Authors: Malcolm P Forbes; Adrienne O'Neil; Melissa Lane; Bruno Agustini; Nick Myles; Michael Berk Journal: Drugs Aging Date: 2021-04-29 Impact factor: 3.923
Authors: Gerald J Haeffel; Bertus F Jeronimus; Bonnie N Kaiser; Lesley Jo Weaver; Peter D Soyster; Aaron J Fisher; Ivan Vargas; Jason T Goodson; Wei Lu Journal: Clin Psychol Sci Date: 2021-05-18
Authors: Christian A Webb; Marie Forgeard; Elana S Israel; Nathaniel Lovell-Smith; Courtney Beard; Thröstur Björgvinsson Journal: J Consult Clin Psychol Date: 2021-04-08